An interventional study of The AquaPass System in Chronic Heart Failure, sponsored by AquaPass Medical Ltd.. Completed at 1 site in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-01.
Sponsored by AquaPass Medical Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Edema with a site in Israel — 1 open to participants now, 1 under way, none of them phase 3. Edema · Israel.
Among the 13 studies in Edema with a site in Israel, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2020, is one of 7 with no phase, and was the 10th registered.
568 studies on the registry are indexed under Edema; 97 are open to participants now.
Browse Edema studies →1 of the 13 studies in Edema with a site in Israel is open now. Recruiting first, the newest first:
Indiana University · Sites in Israel, United States, Argentina and 30 more countries
Ages 0 min–2 wk
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2020.
This study's enrollment of 25 is below the median of 54 across 402 interventional studies indexed under Edema.
Median enrollment 25 across the 11 interventional studies, 4,002 across the 2 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 13 have an industry lead sponsor. The 10 most frequent:
AquaPass Medical Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
AquaPass Medical Ltd. has 3 studies filed under Edema — fewer than ten, so there is no comparison to draw.
1 of the studies in Edema with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Edema with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate safety and performance of AquaPass System for enhancing fluid transfer through the skin, by increased sweat rate, in edematous patients.
This is a prospective, single-center, open label single arm study, conducted in two phases: up to 6 healthy subjects (Phase 1) and up to 16 chronic heart failure (CHF) patients (Phase 2).
After being informed about the study, requirements and potential risks, consenting patients will be enrolled and undergo 3 procedures (each procedure up to 3 (±1) hours operation), with 4-10 days between each procedure.
All patients will be followed up for 7 (±2) days from final procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase 1: Healthy subjects:
Phase 2: CHF Patients:
Exclusion Criteria:
Phase 1: Healthy subjects:
Phase 2: CHF Patients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo 3 procedures (each procedure up to 3 (±1) hours operation) using the AquaPass System, with 4-10 days between each procedure.
Device: The AquaPass System
The AquaPass device is a capsule that creates relatively homogenous temperature around the patients' lower body, while controlling and maintaining at a low percentage the relative humidity within the capsule thus enabling controlled environment that enhances sweat rate.
Safety Events
Device related SAE
Time frame: 30 days
System Activation
Ability to activate the AquaPass System and control skin temperature to levels between 33°C and 38°C
Time frame: During procedure
Treatment Toleration
Subjects can tolerate at least 2 hours of treatment
Time frame: During procedure
Skin Changes
Signs of burns grade 1 or more
Time frame: Before and and immediately after procedure
CBC
Change in Complete Blood Count
Time frame: Before and and immediately after procedure
NT-proBNP (phase 2 only)
Change in N-terminal prohormone of brain natriuretic peptide levels
Time frame: Before and and immediately after procedure
Serum creatinine, BUN and Sodium
Change in serum creatinine, blood urea nitrogen (BUN) and sodium levels
Time frame: Before and and immediately after procedure
Urinary sodium concentration
Change in urinary sodium concentration
Time frame: Before and and immediately after procedure
Dyspnea
Change in dyspnea score
Time frame: Before and and immediately after procedure
Pitting edema
Change in pitting edema score
Time frame: Before and and immediately after procedure
JVD
Change in jugular venous distention (JVD) score
Time frame: Before and and immediately after procedure
Weight
Changes in weight
Time frame: During and and immediately after procedure
Plan to share: No
Ran from Jan 2020 to primary completion in Feb 2022, 24 months.
Of 168 interventional studies with no phase under Edema, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AquaPass Medical Ltd.